The collaboration enables U.S.-based customers to easily and quickly move money via Orum’s Deliver API and Visa Direct NEW YORK, February 26, 2025--(BUSINESS WIRE)--Orum, which transforms ...

Here we highlight a subset of our preferred stocks from the screener. Overview: Orum Therapeutics, Inc. is a biotechnology company focused on researching and developing pharmaceuticals for cancer ...

After withdrawing plans for an IPO last year, Orum Therapeutics Inc. made its debut on the Korea Exchange in 2025 with a ₩50 billion (US$34.7 million) raise as South Korea’s first biopharma IPO of the ...

It expresses the views and opinions of the author. Orum’s transformative solution - a web-based platform built expressly for B2B payments teams - removes the considerable complexity typically ...

Ko­jin Ther­a­peu­tics, a start­up at­tempt­ing to de­vel­op new treat­ments us­ing pro­grammed cell death, left last month’s JP Mor­gan Health­care Con­fer­ence in a bind.

Biotech corporation Orum Therapeutics is strong in early trading on the 14th, the first day of its KOSDAQ listing. As of 9:08 a.m. on this day, Orum Therapeutics is trading at 29,950 won ...

Germany’s Merck MRK-2.82%decrease; red down pointing triangle KGaA said it is in advanced talks for a potential acquisition of SpringWorks Therapeutics SWTX-3.57%decrease; red down pointing ...

Merck KGaA said it’s in advanced talks to purchase SpringWorks Therapeutics Inc., sending shares of the US cancer and rare diseases drugmaker soaring. One of SpringWorks’ drugs, Ogsiveo ...

Update 2:15pm: Adds Merck KGaA confirmation. SpringWorks Therapeutics (NASDAQ:SWTX) soared ~40% after a report that Merck KGaA (OTCPK:MKGAF) is in advanced discussions to acquire the cancer and ...

SpringWorks Therapeutics (NASDAQ:SWTX) may be valued at about $77 a share in a possible takeover after a report earlier that Merck KGaA (OTCPK:MKGAF) is in talks for a purchase of the cancer and ...